|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ZEB2 |
Gene summary for ZEB2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ZEB2 | Gene ID | 9839 |
| Gene name | zinc finger E-box binding homeobox 2 | |
| Gene Alias | HSPC082 | |
| Cytomap | 2q22.3 | |
| Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | O60315 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 9839 | ZEB2 | CA_HPV_1 | Human | Cervix | CC | 5.83e-03 | 4.03e-01 | 0.0264 |
| 9839 | ZEB2 | CA_HPV_3 | Human | Cervix | CC | 1.79e-02 | -2.73e-01 | 0.0414 |
| 9839 | ZEB2 | CCII_1 | Human | Cervix | CC | 3.70e-08 | -5.55e-01 | 0.3249 |
| 9839 | ZEB2 | Tumor | Human | Cervix | CC | 4.80e-29 | -5.86e-01 | 0.1241 |
| 9839 | ZEB2 | sample1 | Human | Cervix | CC | 1.94e-04 | -5.13e-01 | 0.0959 |
| 9839 | ZEB2 | sample3 | Human | Cervix | CC | 1.30e-30 | -5.80e-01 | 0.1387 |
| 9839 | ZEB2 | H2 | Human | Cervix | HSIL_HPV | 1.04e-26 | -5.74e-01 | 0.0632 |
| 9839 | ZEB2 | L1 | Human | Cervix | CC | 4.25e-07 | -4.50e-01 | 0.0802 |
| 9839 | ZEB2 | T1 | Human | Cervix | CC | 4.44e-06 | -4.24e-01 | 0.0918 |
| 9839 | ZEB2 | T2 | Human | Cervix | CC | 7.15e-03 | -5.43e-01 | 0.0709 |
| 9839 | ZEB2 | T3 | Human | Cervix | CC | 1.35e-26 | -5.87e-01 | 0.1389 |
| 9839 | ZEB2 | P9T-E | Human | Esophagus | ESCC | 3.82e-03 | 2.68e-01 | 0.1131 |
| 9839 | ZEB2 | P11T-E | Human | Esophagus | ESCC | 6.43e-12 | 8.34e-01 | 0.1426 |
| 9839 | ZEB2 | P12T-E | Human | Esophagus | ESCC | 5.09e-06 | 1.60e-01 | 0.1122 |
| 9839 | ZEB2 | P19T-E | Human | Esophagus | ESCC | 1.72e-09 | 1.14e+00 | 0.1662 |
| 9839 | ZEB2 | P24T-E | Human | Esophagus | ESCC | 2.35e-03 | 3.29e-01 | 0.1287 |
| 9839 | ZEB2 | P32T-E | Human | Esophagus | ESCC | 6.42e-16 | 4.96e-01 | 0.1666 |
| 9839 | ZEB2 | P37T-E | Human | Esophagus | ESCC | 2.57e-04 | 2.11e-01 | 0.1371 |
| 9839 | ZEB2 | P44T-E | Human | Esophagus | ESCC | 1.36e-04 | 3.25e-01 | 0.1096 |
| 9839 | ZEB2 | P49T-E | Human | Esophagus | ESCC | 3.17e-02 | 4.22e-01 | 0.1768 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:009013210 | Cervix | CC | epithelium migration | 90/2311 | 360/18723 | 2.45e-11 | 6.11e-09 | 90 |
| GO:00016679 | Cervix | CC | ameboidal-type cell migration | 110/2311 | 475/18723 | 2.66e-11 | 6.36e-09 | 110 |
| GO:001063110 | Cervix | CC | epithelial cell migration | 89/2311 | 357/18723 | 3.72e-11 | 8.54e-09 | 89 |
| GO:009013010 | Cervix | CC | tissue migration | 90/2311 | 365/18723 | 5.42e-11 | 1.05e-08 | 90 |
| GO:00160557 | Cervix | CC | Wnt signaling pathway | 98/2311 | 444/18723 | 4.82e-09 | 4.65e-07 | 98 |
| GO:01987387 | Cervix | CC | cell-cell signaling by wnt | 98/2311 | 446/18723 | 6.16e-09 | 5.58e-07 | 98 |
| GO:00301117 | Cervix | CC | regulation of Wnt signaling pathway | 76/2311 | 328/18723 | 3.05e-08 | 2.08e-06 | 76 |
| GO:00608287 | Cervix | CC | regulation of canonical Wnt signaling pathway | 58/2311 | 253/18723 | 1.83e-06 | 5.89e-05 | 58 |
| GO:00600707 | Cervix | CC | canonical Wnt signaling pathway | 66/2311 | 303/18723 | 2.47e-06 | 7.35e-05 | 66 |
| GO:00071786 | Cervix | CC | transmembrane receptor protein serine/threonine kinase signaling pathway | 67/2311 | 355/18723 | 2.39e-04 | 2.67e-03 | 67 |
| GO:00715595 | Cervix | CC | response to transforming growth factor beta | 50/2311 | 256/18723 | 6.31e-04 | 5.91e-03 | 50 |
| GO:00715605 | Cervix | CC | cellular response to transforming growth factor beta stimulus | 49/2311 | 250/18723 | 6.55e-04 | 6.05e-03 | 49 |
| GO:00301776 | Cervix | CC | positive regulation of Wnt signaling pathway | 31/2311 | 140/18723 | 8.01e-04 | 7.02e-03 | 31 |
| GO:00160506 | Cervix | CC | vesicle organization | 54/2311 | 300/18723 | 2.71e-03 | 1.85e-02 | 54 |
| GO:00071795 | Cervix | CC | transforming growth factor beta receptor signaling pathway | 38/2311 | 198/18723 | 3.62e-03 | 2.31e-02 | 38 |
| GO:00902636 | Cervix | CC | positive regulation of canonical Wnt signaling pathway | 22/2311 | 106/18723 | 9.52e-03 | 4.72e-02 | 22 |
| GO:001063113 | Cervix | HSIL_HPV | epithelial cell migration | 33/737 | 357/18723 | 5.28e-06 | 2.04e-04 | 33 |
| GO:000166715 | Cervix | HSIL_HPV | ameboidal-type cell migration | 40/737 | 475/18723 | 5.48e-06 | 2.07e-04 | 40 |
| GO:009013213 | Cervix | HSIL_HPV | epithelium migration | 33/737 | 360/18723 | 6.31e-06 | 2.29e-04 | 33 |
| GO:009013013 | Cervix | HSIL_HPV | tissue migration | 33/737 | 365/18723 | 8.43e-06 | 2.97e-04 | 33 |
| Page: 1 2 3 4 5 6 7 8 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ZEB2 | SNV | Missense_Mutation | novel | c.2669N>A | p.Ser890Asn | p.S890N | O60315 | protein_coding | deleterious(0.05) | benign(0.035) | TCGA-3C-AAAU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | zoladex | SD |
| ZEB2 | SNV | Missense_Mutation | novel | c.3206C>T | p.Ser1069Leu | p.S1069L | O60315 | protein_coding | deleterious(0) | probably_damaging(0.968) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
| ZEB2 | SNV | Missense_Mutation | novel | c.1827G>C | p.Glu609Asp | p.E609D | O60315 | protein_coding | tolerated(0.23) | probably_damaging(0.989) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
| ZEB2 | SNV | Missense_Mutation | novel | c.34N>G | p.Cys12Gly | p.C12G | O60315 | protein_coding | deleterious(0.01) | benign(0.007) | TCGA-A2-A04P-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxol | PD |
| ZEB2 | SNV | Missense_Mutation | c.3289N>A | p.Glu1097Lys | p.E1097K | O60315 | protein_coding | tolerated(0.17) | probably_damaging(0.972) | TCGA-A8-A092-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | CR | |
| ZEB2 | SNV | Missense_Mutation | c.3280N>A | p.Glu1094Lys | p.E1094K | O60315 | protein_coding | deleterious(0.02) | benign(0.444) | TCGA-A8-A09G-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| ZEB2 | SNV | Missense_Mutation | c.270G>T | p.Glu90Asp | p.E90D | O60315 | protein_coding | tolerated(0.91) | benign(0) | TCGA-AR-A250-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| ZEB2 | SNV | Missense_Mutation | c.1204N>C | p.Val402Leu | p.V402L | O60315 | protein_coding | tolerated(0.39) | benign(0) | TCGA-BH-A0AV-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR | |
| ZEB2 | SNV | Missense_Mutation | c.3547N>A | p.Glu1183Lys | p.E1183K | O60315 | protein_coding | tolerated_low_confidence(0.1) | benign(0.039) | TCGA-BH-A0B3-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | |
| ZEB2 | SNV | Missense_Mutation | rs730881174 | c.905N>A | p.Arg302Gln | p.R302Q | O60315 | protein_coding | deleterious(0) | probably_damaging(0.979) | TCGA-BH-A0HI-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |